RT Journal Article
SR Electronic
T1 Development and clinical evaluation of a monkeypox antigen-detecting rapid diagnostic test
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.06.24313376
DO 10.1101/2024.10.06.24313376
A1 Kurosawa, Nobuyuki
A1 Ozawa, Tatsuhiko
A1 Ozawa, Kousei
A1 Shimojima, Masayuki
A1 Kawahara, Madoka
A1 Kasuya, Fumi
A1 Okada, Wakaba
A1 Nagashima, Mami
A1 Sadamasu, Kenji
A1 Itamochi, Masae
A1 Tani, Hideki
A1 Morinaga, Yoshitomo
A1 Yuhara, Kosuke
A1 Okamoto, Jun
A1 Ichikawa, Haruna
A1 Kawahata, Takashi
A1 Yamazaki, Tomomi
A1 Isobe, Masaharu
YR 2024
UL http://medrxiv.org/content/early/2024/10/10/2024.10.06.24313376.abstract
AB To address the global emergence of monkeypox after the 2022 epidemic, a rapid and accurate diagnostic tool is needed at the point of care to identify individuals infected with monkeypox virus (MPXV) to prevent and control the spread of the virus. We designed an antigen-detecting rapid diagnostic test that exclusively detects MPXV without cross-reacting with the vaccinia virus by developing monoclonal antibodies against the MPXV nuclear capsid protein A5L (MPXV-A5L). The test established a limit of detection sensitivity of 0.5 ng/mL of MPXV-A5L, with high sensitivity (87%) for clinical specimens collected from MPXV patients, a qPCR cycle threshold value ≤ 25 and 100% specificity for qPCR-negative samples. The test is an ideal rapid diagnostic tool for supporting clinical decision-making for people suspected of having MPXV infection in resource-poor settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by grants from the Japan Agency for Medical Research and Development (AMED) to Masaharu Isobe (19187977, 20333128 and 22723616) and Tatsuhiko Ozawa (JP24ama121010), as well as from The Toyama Pharmaceutical Valley Development Consortium (no grant number assigned) to Masaharu Isobe and Japan Society for the Promotion of Science, Japan (Grant in Aid for Scientific Research B) (22H02875) to Nobuyuki Kurosawa. The funders had no role in the study design, data collection and analysis, publishing decisions, or the preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University of Toyama gave ethical approval for this work (R2023227). Ethics committee of Tokyo Metropolitan Institute of Public Health gave ethical approval for this work (5 KenKenKen 3712 )I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.Ag-RDTantigen-detecting rapid diagnostic testMPXVmonkeypox virusOPXVorthopoxvirusqPCRquantitative polymerase chain reactionLFIAlateral flow immunochromatography assayVACVvaccinia virusesCtcycle threshold